Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics
Top Cited Papers
Open Access
- 25 February 2025
- journal article
- review article
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 12 (4) , 100094
Abstract
No abstract availableKeywords
This publication has 106 references indexed in Scilit:
- Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary CareJAMA, 2024
- Use of Lecanemab for Patients With Cardiovascular DiseaseJAMA, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer DiseaseJAMA Neurology, 2021
- Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related InflammationJAMA Neurology, 2020
- Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy–Related InflammationJAMA Neurology, 2016
- Autosomal Recessive Causes Likely in Early-Onset Alzheimer DiseaseArchives of Neurology, 2012
- Use of Florbetapir-PET for Imaging β-Amyloid PathologyJAMA, 2011
- Mild Cognitive ImpairmentArchives of Neurology, 1999
- The Prevalence and Malignancy of Alzheimer DiseaseArchives of Neurology, 1976